Bas Van Der Woning

Gent, VLG 9052, Belgium

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

Antibody-mediated TGF-β1 activation for the treatment of diseases caused by deleterious T cell activity.

Antibody-mediated TGF-β1 activation for the treatment of diseases caused by deleterious T cell activity.

Journal: Cell reports
Published: December 20, 2024

Site-directed multivalent conjugation of antibodies to ubiquitinated payloads.

Site-directed multivalent conjugation of antibodies to ubiquitinated payloads.

Journal: Nature biomedical engineering
Published: March 26, 2024

TR-FRET between engineered nanobodies reveals the existence of endogenous CXCR4 oligomers.

TR-FRET between engineered nanobodies reveals the existence of endogenous CXCR4 oligomers.

Journal: Communications biology
Published: November 20, 2023

Efgartigimod restores muscle function in a humanized mouse model of immune-mediated necrotizing myopathy.

Efgartigimod restores muscle function in a humanized mouse model of immune-mediated necrotizing myopathy.

Journal: Rheumatology (Oxford, England)
Published: January 11, 2023

Chemokine switch regulated by TGF-β1 in cancer-associated fibroblast subsets determines the efficacy of chemo-immunotherapy.

Chemokine switch regulated by TGF-β1 in cancer-associated fibroblast subsets determines the efficacy of chemo-immunotherapy.

Journal: Oncoimmunology
Published: November 17, 2022

The Charcot-Leyden crystal protein galectin-10 is not a major determinant of human regulatory T-cell function.

The Charcot-Leyden crystal protein galectin-10 is not a major determinant of human regulatory T-cell function.

Journal: Allergy
Published: October 25, 2021

Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer.

Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer.

Journal: Nature communications
Published: January 21, 2020

Antibodies Targeting Chemokine Receptors CXCR4 and ACKR3.

Antibodies Targeting Chemokine Receptors CXCR4 and ACKR3.

Journal: Molecular pharmacology
Published: April 22, 2019

Display Technologies for Generation of Ig Single Variable Domains.

Display Technologies for Generation of Ig Single Variable Domains.

Journal: Methods in molecular biology (Clifton, N.J.)
Published: September 10, 2018

Structural basis of latent TGF-β1 presentation and activation by GARP on human regulatory T cells.

Structural basis of latent TGF-β1 presentation and activation by GARP on human regulatory T cells.

Journal: Science (New York, N.Y.)
Published: May 25, 2018

Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functions.

Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functions.

Journal: Biochemical pharmacology
Published: May 25, 2018

CXCR4-targeting nanobodies differentially inhibit CXCR4 function and HIV entry.

CXCR4-targeting nanobodies differentially inhibit CXCR4 function and HIV entry.

Journal: Biochemical pharmacology
Published: May 25, 2018
Showing 1-12 of 16

Last Updated: 09/26/2026